You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for New Drug Application (NDA): 211843


✉ Email this page to a colleague

« Back to Dashboard


NDA 211843 describes THIOLA EC, which is a drug marketed by Mission Pharmacal and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the THIOLA EC profile page.

The generic ingredient in THIOLA EC is tiopronin. There are three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the tiopronin profile page.
Summary for 211843
Tradename:THIOLA EC
Applicant:Mission Pharmacal
Ingredient:tiopronin
Patents:1
Pharmacology for NDA: 211843
Mechanism of ActionCystine Disulfide Reduction
Suppliers and Packaging for NDA: 211843
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
THIOLA EC tiopronin TABLET, DELAYED RELEASE;ORAL 211843 NDA Mission Pharmacal Company 0178-0901 0178-0901-90 90 TABLET, DELAYED RELEASE in 1 BOTTLE (0178-0901-90)
THIOLA EC tiopronin TABLET, DELAYED RELEASE;ORAL 211843 NDA Mission Pharmacal Company 0178-0902 0178-0902-01 300 TABLET, DELAYED RELEASE in 1 BOTTLE (0178-0902-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength100MG
Approval Date:Jun 28, 2019TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jun 28, 2026
Regulatory Exclusivity Use:FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Patent:11,458,104Patent Expiration:Nov 14, 2038Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING CYSTINURIA BY ORALLY ADMINISTERING TIOPRONIN WITH FOOD TO PREVENT CYSTINE STONE FORMATION IN ADULTS AND PEDIATRIC PATIENTS WITH SEVERE HOMOZYGOUS CYSTINURIA

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength300MG
Approval Date:Jun 28, 2019TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jun 28, 2026
Regulatory Exclusivity Use:FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.